ONC-392,Pembrolizumab,Ipilimumab
biontech,Merck,BMS
['action i']
i don t know if i m just tired, but this data from onc-392 is really something, right? 29.6% orr after pd-(l)1 progression with less iraes when compared to ipi. this novel - or different - mechanism of action is quite something. #asco23 
Husband, Father.
Medical Oncologist and Researcher focused in Thoracic Oncology.
Views are my own.